NICE backs Herceptin
Two weeks after Herceptin was licensed by regulatory authorities for use in early breast cancer, NICE has issued draft guidance recommending the drug for women with early state HER2-positive breast cancer, except where there are concerns about the woman's cardiac function.
Two weeks after Herceptin was licensed by regulatory authorities for use in early breast cancer, the UK's National Institute for Clinical Excellence (NICE) has issued draft guidance recommending the drug for women with early stage HER2-positive breast cancer, except where there are concerns about the woman's cardiac function.
Once final guidance is published in July, there will be a 3-month grace period for its implementation and anyone failing to offer Herceptin to eligible patients may face legal proceedings. NICE chief executive Andrew Dillon said that the treatment is clinically- and cost-effective in the early stage of the disease.
Herceptin (trastuzumab) is a monoclonal antibody that targets breast cancer cells. According to Cancer Research UK, 15–25% of breast cancer patients are likely to respond to treatment with Herceptin. The treatment blocks the cancer cells' ability to grow, and increases the effect of chemotherapy drugs on breast cancer cells.
More than 5000 women in the UK are eligible for treatment by Herceptin. However, at an estimated £100 million a year, the UK National Health Service (NHS) Confederation has warned that cutbacks elsewhere may be necessary.
www.nice.org.uk
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Amgen’s Imdelltra Demonstrates Significant Overall Survival Improvement in Small Cell Lung Cancer
April 16th 2025In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically significant and clinically meaningful improvement in overall survival compared to standard-of-care chemotherapy.
